AU2019248516B2 - Implantable particles and related methods - Google Patents

Implantable particles and related methods Download PDF

Info

Publication number
AU2019248516B2
AU2019248516B2 AU2019248516A AU2019248516A AU2019248516B2 AU 2019248516 B2 AU2019248516 B2 AU 2019248516B2 AU 2019248516 A AU2019248516 A AU 2019248516A AU 2019248516 A AU2019248516 A AU 2019248516A AU 2019248516 B2 AU2019248516 B2 AU 2019248516B2
Authority
AU
Australia
Prior art keywords
particle
compartment
compound
cell
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019248516A
Other languages
English (en)
Other versions
AU2019248516A1 (en
Inventor
Lauren Emily Barney
Michael Beauregard
Guillaume Carmona
Francisco Caballero Gonzalez
Richard Heidebrecht
Erika Ellen Johnston
Robert James Miller
Owen O'connor
Matthias Alexander Oberli
David Peritt
Jared A. Sewell
Devyn McKinley SMITH
Omid Veiseh
Paul Kevin Wotton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigilon Therapeutics Inc
Original Assignee
Sigilon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigilon Therapeutics Inc filed Critical Sigilon Therapeutics Inc
Publication of AU2019248516A1 publication Critical patent/AU2019248516A1/en
Priority to AU2025202824A priority Critical patent/AU2025202824A1/en
Application granted granted Critical
Publication of AU2019248516B2 publication Critical patent/AU2019248516B2/en
Priority to AU2025213622A priority patent/AU2025213622A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/04—Alginic acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
AU2019248516A 2018-04-04 2019-03-27 Implantable particles and related methods Active AU2019248516B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2025202824A AU2025202824A1 (en) 2018-04-04 2025-04-23 Implantable particles and related methods
AU2025213622A AU2025213622A1 (en) 2018-04-04 2025-08-07 Implantable particles and related methods

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862652880P 2018-04-04 2018-04-04
US62/652,880 2018-04-04
US201862737838P 2018-09-27 2018-09-27
US62/737,838 2018-09-27
US201962812568P 2019-03-01 2019-03-01
US62/812,568 2019-03-01
PCT/US2019/024371 WO2019195055A1 (en) 2018-04-04 2019-03-27 Implantable particles and related methods

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2025202824A Division AU2025202824A1 (en) 2018-04-04 2025-04-23 Implantable particles and related methods
AU2025213622A Division AU2025213622A1 (en) 2018-04-04 2025-08-07 Implantable particles and related methods

Publications (2)

Publication Number Publication Date
AU2019248516A1 AU2019248516A1 (en) 2020-10-15
AU2019248516B2 true AU2019248516B2 (en) 2025-05-08

Family

ID=66102321

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2019248516A Active AU2019248516B2 (en) 2018-04-04 2019-03-27 Implantable particles and related methods
AU2025202824A Abandoned AU2025202824A1 (en) 2018-04-04 2025-04-23 Implantable particles and related methods
AU2025213622A Pending AU2025213622A1 (en) 2018-04-04 2025-08-07 Implantable particles and related methods

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2025202824A Abandoned AU2025202824A1 (en) 2018-04-04 2025-04-23 Implantable particles and related methods
AU2025213622A Pending AU2025213622A1 (en) 2018-04-04 2025-08-07 Implantable particles and related methods

Country Status (14)

Country Link
US (2) US12161760B2 (enExample)
EP (1) EP3773517A1 (enExample)
JP (2) JP7534219B2 (enExample)
KR (1) KR20210005608A (enExample)
CN (1) CN112203646A (enExample)
AU (3) AU2019248516B2 (enExample)
BR (1) BR112020020084A2 (enExample)
CA (1) CA3096038A1 (enExample)
IL (2) IL312315A (enExample)
MX (1) MX2020010369A (enExample)
NZ (1) NZ768232A (enExample)
TW (1) TW202014181A (enExample)
UY (1) UY38160A (enExample)
WO (1) WO2019195055A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3687580A1 (en) * 2017-09-27 2020-08-05 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
US20210196646A1 (en) * 2018-08-15 2021-07-01 Wake Forest University Health Sciences Improved formulations for pancreatic islet encapsulation
UY38389A (es) * 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
EP4061942A4 (en) 2019-11-22 2023-12-20 Sigilon Therapeutics, Inc. MONOCLONAL CELL LINES EXPRESSING AN EXOGENEOUS SUBSTANCE AND THEIR USES
US12306081B2 (en) 2019-12-04 2025-05-20 Sigilon Therapeutics, Inc. Apparatuses and methods for formation of particles
US20230045277A1 (en) * 2019-12-13 2023-02-09 Sigilon Therapeutics, Inc. Compounds, polymers, devices, and uses thereof
WO2021226137A1 (en) * 2020-05-04 2021-11-11 Sigilon Therapeutics, Inc. Compositions, devices and methods for inducing immune responses to infectious agents
WO2022026606A2 (en) * 2020-07-28 2022-02-03 Sigilon Therapeutics, Inc. Genetically modified cell lines expressing an exogenous substance and uses thereof
CA3190778A1 (en) * 2020-08-04 2022-02-10 Sigilon Therapeutics, Inc. Heteroaryl and heterocyclyl compounds
WO2022164933A2 (en) * 2021-01-26 2022-08-04 Sigilon Therapeutics, Inc. Biocompatible devices for cell-based therapies and related methods
CA3209738A1 (en) * 2021-01-26 2022-08-04 Sigilon Therapeutics, Inc. Compositions, devices and methods for treating immune-mediated inflammatory diseases
CN117042723A (zh) * 2021-01-26 2023-11-10 西吉隆医疗股份有限公司 用于诱导抗原特异性免疫耐受的组合物、装置和方法
EP4288535A4 (en) * 2021-02-05 2024-12-18 Sigilon Therapeutics, Inc. COMPOSITIONS, DEVICES AND METHODS FOR TREATING MPS TYPE VI
EP4419546A1 (en) * 2021-10-20 2024-08-28 William Marsh Rice University Encapsulated cells expressing il-2 and uses thereof
WO2023230524A1 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vi, Llc Compositions of secretory and/or catalytic cells and methods using the same
WO2023235884A1 (en) 2022-06-03 2023-12-07 Flagship Pioneering Innovations Vi, Llc Compositions and methods
CN119546647A (zh) 2022-07-01 2025-02-28 西吉隆医疗股份有限公司 共价光交联多糖及其使用方法
CA3264517A1 (en) * 2022-08-29 2024-03-07 Celanese Eva Performance Polymers Llc IMPLANTABLE DEVICE FOR THE INTRATUMORAL ADMINISTRATION OF A THERAPEUTIC AGENT
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024191428A1 (en) 2023-03-14 2024-09-19 Sigilon Therapeutics, Inc. Hydrogel capsules comprising covalently photocrosslinked polysaccharides and islet cells
WO2025117331A1 (en) 2023-12-01 2025-06-05 Eli Lilly And Company Methods of making stem cell-derived islet-like cells, as well as populations and compositions including the same
WO2026026907A1 (zh) * 2024-07-31 2026-02-05 北京拓界生物医药科技有限公司 一种修饰的聚合物及其用途
WO2026026917A1 (zh) * 2024-07-31 2026-02-05 北京拓界生物医药科技有限公司 一种修饰的聚合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160030359A1 (en) * 2013-03-14 2016-02-04 Massachusetts Institute Of Technology Multi-Layer Hydrogel Capsules for Encapsulation of Cells and Cell Aggregates
US20160030360A1 (en) * 2014-08-01 2016-02-04 Massachusetts Institute Of Technology Modified alginates for anti-fibrotic materials and applications

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8801674A1 (es) 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
DE3785102T2 (de) 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
ATE156344T1 (de) * 1991-04-25 1997-08-15 Univ Brown Res Found Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
US5578314A (en) 1992-05-29 1996-11-26 The Regents Of The University Of California Multiple layer alginate coatings of biological tissue for transplantation
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5876742A (en) * 1994-01-24 1999-03-02 The Regents Of The University Of California Biological tissue transplant coated with stabilized multilayer alginate coating suitable for transplantation and method of preparation thereof
US6126936A (en) * 1995-03-10 2000-10-03 Biohybrid Technologies Llc Microcapsules and composite microreactors for immunoisolation of cells
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
AU2798599A (en) 1998-02-27 1999-09-15 Bioelastics Research Ltd. Injectable implants for tissue augmentation and restoration
US20090148906A1 (en) 1998-09-29 2009-06-11 Shire Human Genetic Therapies, Inc. A Delaware Corporation Optimized messenger rna
US6361771B1 (en) 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
CZ20032454A3 (en) 2001-03-22 2004-03-17 Novo Nordisk Health Care Ag Coagulation factor vii derivative
CA2445568A1 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
MXPA04001982A (es) 2001-09-04 2004-06-07 Merck Patent Gmbh Factor ix modificado.
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
CA2519873C (en) 2003-03-20 2012-12-18 Maxygen Holdings Ltd. Fvii or fviia variants
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
EP1761630A2 (en) 2004-06-21 2007-03-14 Novo Nordisk Health Care AG Glycosylation-disrupted factor vii variants
EP2032607B2 (en) 2006-06-14 2017-02-22 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
EP2423307A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
US20080242694A1 (en) 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
CN102026653B (zh) 2007-10-15 2014-06-18 北卡罗来纳-查佩尔山大学 半衰期延长的人因子ⅸ变体
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
JP2011517950A (ja) 2008-04-16 2011-06-23 バイエル・ヘルスケア・エルエルシー 第ｉｘ因子の部位特異的修飾
SG189790A1 (en) 2008-04-16 2013-05-31 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
US20110137011A1 (en) 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
WO2010005533A2 (en) 2008-06-30 2010-01-14 The Johns Hopkins University Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa
AU2010206374B2 (en) 2009-01-23 2013-01-17 Gloriana Therapeutics Sarl Improved cell lines and their use in encapsulated cell biodelivery
WO2010111617A2 (en) 2009-03-27 2010-09-30 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
WO2011020866A2 (en) 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
PT2482841T (pt) 2009-10-02 2019-03-01 Childrens Hospital Philadelphia A presente invenção refere-se à utilização de lactonas macrocíclicas para o tratamento da demodicose, em particular em cães.
US8383417B2 (en) 2009-12-22 2013-02-26 Thermo Finnigan, Llc Assay for monitoring parathyroid hormone (PTH) variants by tandem mass spectrometry
JP5725475B2 (ja) 2010-01-21 2015-05-27 公立大学法人名古屋市立大学 ヒドロキサム酸誘導体及びそれを用いたｈｄａｃ８阻害剤
PL3552619T3 (pl) 2010-07-09 2025-12-01 Bioverativ Therapeutics Inc. Polipeptydy czynnika ix i sposoby ich zastosowania
US20130217630A1 (en) 2010-10-26 2013-08-22 ARIZONA BOARD OF REGENTS, a body corporate of the State of Arizona, acting for an on behalf of Arizo Parathyroid hormone variants and assays related to disease
US9867781B2 (en) 2011-02-18 2018-01-16 Massachusetts Institute Of Technology Hydrogel encapsulated cells and anti-inflammatory drugs
DK3354665T5 (da) 2011-06-02 2022-09-19 Massachusetts Inst Technology Modificerede alginater til celleindkapsling og celleterapi
KR20140084208A (ko) 2011-10-18 2014-07-04 시에스엘 리미티드 정제된 인자 ｖｉｉｉ의 재구성 후의 안정성을 향상시키는 방법
WO2013120939A1 (en) 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
ES2845473T3 (es) 2013-03-14 2021-07-26 Boehringer Ingelheim Int (Bencil-ciano-metil)-amidas sustituidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico inhibidores de la catepsina- C
US9555007B2 (en) * 2013-03-14 2017-01-31 Massachusetts Institute Of Technology Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates
GB201304973D0 (en) 2013-03-19 2013-05-01 Profactor Pharma Ltd Recombinant protein
ITTO20130356A1 (it) 2013-05-03 2014-11-04 Uni Degli Studi Del Piemonte Orientale Ame Inibitori di nicotinamide fosforibosil transferasi, relative composizioni, prodotti ed usi
WO2014182684A2 (en) 2013-05-06 2014-11-13 Cell Machines, Inc. Methods and compositions related to large scale production of proteins
CA2922483A1 (en) 2013-09-11 2015-03-19 Neurotech Usa, Inc. Encapsulated cell therapy cartridge
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
PL3628334T3 (pl) 2014-03-21 2023-12-18 Genzyme Corporation Terapia genowa w retinopatii barwnikowej
CN104072478B (zh) 2014-05-22 2016-06-01 大连理工大学 一类萘环4位含1,2,3-三唑的萘酰亚胺衍生物的合成及其应用
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
AU2015301936B2 (en) 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
EP3297693A1 (en) 2015-05-17 2018-03-28 Massachusetts Institute of Technology Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates
JPWO2017018086A1 (ja) 2015-07-29 2018-02-01 Ｎｉｓｓｈａ株式会社 マイクロニードルシート
IL242380A0 (en) 2015-10-29 2016-02-01 Yeda Res & Dev A method of inducing cardiomyocytes proliferation and treating heart diseases
AU2016344041B2 (en) 2015-11-01 2019-11-07 Massachusetts Institute Of Technology Materials with improved properties
NZ742800A (en) 2015-11-01 2019-03-29 Massachusetts Inst Technology Modified alginates for anti-fibrotic materials and applications
CA3012695A1 (en) 2016-02-01 2017-08-10 Bioverativ Therapeutics Inc. Optimized factor viii genes
WO2017201328A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE
KR20190092374A (ko) 2016-10-03 2019-08-07 시질론 테라퓨틱스, 인크. 화합물, 장치, 및 이의 용도
WO2018206168A1 (en) 2017-05-11 2018-11-15 Zentrum Für Forschungsförderung In Der Pädiatrie Gmbh Concept for the treatment of monogenetic disorders
EP3687580A1 (en) 2017-09-27 2020-08-05 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160030359A1 (en) * 2013-03-14 2016-02-04 Massachusetts Institute Of Technology Multi-Layer Hydrogel Capsules for Encapsulation of Cells and Cell Aggregates
US20160030360A1 (en) * 2014-08-01 2016-02-04 Massachusetts Institute Of Technology Modified alginates for anti-fibrotic materials and applications

Also Published As

Publication number Publication date
IL277713A (en) 2020-11-30
AU2025202824A1 (en) 2025-05-08
IL312315A (en) 2024-06-01
CA3096038A1 (en) 2019-10-10
IL277713B1 (en) 2024-05-01
US12161760B2 (en) 2024-12-10
TW202014181A (zh) 2020-04-16
KR20210005608A (ko) 2021-01-14
JP7534219B2 (ja) 2024-08-14
MX2020010369A (es) 2020-10-22
IL277713B2 (en) 2024-09-01
CN112203646A (zh) 2021-01-08
JP2024056145A (ja) 2024-04-22
US20210145759A1 (en) 2021-05-20
BR112020020084A2 (pt) 2021-01-05
NZ768232A (en) 2025-11-28
AU2019248516A1 (en) 2020-10-15
US20250235409A1 (en) 2025-07-24
UY38160A (es) 2019-11-29
AU2025213622A1 (en) 2025-09-11
EP3773517A1 (en) 2021-02-17
JP2021520374A (ja) 2021-08-19
RU2020136050A (ru) 2022-05-06
WO2019195055A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
AU2019248516B2 (en) Implantable particles and related methods
KR20210102194A (ko) 세포 치료법을 위한 이식 가능한 디바이스 및 관련 방법
CN111372612A (zh) 包含活性细胞的方法、组合物和可植入元件
KR20220058489A (ko) 인자 vii 요법을 위한 조성물, 디바이스 및 방법
TW202309034A (zh) Dna依賴性蛋白質激酶抑制劑以及其組合物及用途
RU2826206C2 (ru) Способы, композиции и имплантируемые элементы, содержащие активные клетки
WO2024006551A2 (en) Covalently crosslinked polysaccharides and methods of use thereof
RU2833057C2 (ru) Имплантируемые частицы и соответствующие способы
EP4547245A2 (en) Covalently crosslinked polysaccharides and methods of use thereof
CN111732667A (zh) 小反刍兽疫病毒基因工程亚单位疫苗

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)